ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference
24 March 2021 - 9:33PM
Business Wire
ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief
Executive Officer, Rob Fried, and Chief Financial Officer, Kevin
Farr, will be presenting virtually at the Lytham Partners Spring
2021 Investor Conference.
The ChromaDex management team is scheduled to present on
Wednesday, March 31, 2021 at 10:15 a.m. Eastern Time (7:15 a.m.
Pacific Time).
The presentation will be webcast live via the link below on the
investor relations section of the Company’s website at
www.chromadex.com or can be accessed here. The webcast will also be
archived and available for replay following the live event.
Management will also be participating in virtual one-on-one
meetings throughout the event, which runs from March 30, 2021
through April 1, 2021. To arrange a meeting, please contact Lytham
Partners at 1x1@lythampartners.com.
Webcast link: ChromaDex Investor Presentation – Lytham
Partners
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex delivers Niagen® as the sole active
ingredient in its consumer product Tru Niagen® available at
www.truniagen.com and through partnerships with global retailers
and distributors. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2020, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210324005269/en/
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing and Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2024 to May 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From May 2023 to May 2024